🏡 Home≡ MenuNewsA - Z

New Prolastin Version Approved by FDA

  • Date: 2009/10/19 Talecris Biotherapeutics
  • Synopsis : PROLASTIN-C increases or augments protein levels in AAT-deficient patients at risk for developing emphysema.

Main Document

Talecris Biotherapeutics today received approval from the U.S. Food and Drug Administration for PROLASTIN-C (Alpha1-Proteinase Inhibitor [Human]), a more concentrated version of PROLASTIN produced using advances in manufacturing technology.

Like PROLASTIN, the market leader for over 20 years, PROLASTIN-C is indicated for the treatment of alpha1-antitrypsin (AAT) deficiency, a genetic condition in which low levels of this essential protein can result in emphysema. The active protein in PROLASTIN-C increases or "augments" protein levels in AAT-deficient patients at risk for developing emphysema.

PROLASTIN-C delivers twice the active protein per milliliter as PROLASTIN, cutting infusion volume and time in half when given at the recommended rate of 0.08 mL/kg/min. Clinical studies have shown that PROLASTIN-C and PROLASTIN are equally effective at raising AAT levels in the blood, and that the adverse event profile of PROLASTIN-C is consistent with that of PROLASTIN. The most common drug-related adverse reactions observed at a rate of >/=1% in subjects receiving PROLASTIN-C were chills, malaise, headache, rash, hot flush and pruritus.

"The introduction of PROLASTIN revolutionized care for thousands of individuals with Alpha-1," said John Walsh, president and CEO of the Alpha-1 Foundation. "We welcome PROLASTIN-C as an example of the ongoing commitment Talecris has made to the Alpha-1 community."

The manufacturing process for PROLASTIN-C incorporates technological advances such as nano-filtration, a virus exclusion technology, and cation exchange chromatography, an additional purification step.

"PROLASTIN-C is an example of the significant investments Talecris is making in research and development and manufacturing," said Steve Petteway, Ph.D., executive vice president, Research and Development. "Our single-minded goal is advancing the care of patients who rely on our products."

PROLASTIN DIRECT, the exclusive distribution and health management program for PROLASTIN, will provide more information to patients in the U.S. about the transition to PROLASTIN-C. Information about the transition to PROLASTIN-C in other countries will be provided as regulatory approvals are granted.

About PROLASTIN® and PROLASTIN®-C

PROLASTIN and PROLASTIN-C, Alpha1-Proteinase Inhibitor (Human), are derived from human plasma and are administered intravenously to raise the levels of AAT in the blood and lungs. PROLASTIN and PROLASTIN-C are indicated for chronic augmentation and maintenance therapy of individuals having congenital deficiency of alpha-1 PI (alpha1-antitrypsin deficiency) with clinically demonstrable panacinar emphysema. PROLASTIN was the first plasma-derived AAT augmentation therapy to receive approval from the U.S. Food and Drug Administration (FDA) and was approved in December 1987 and launched in February 1988.

Important Safety Information

In clinical studies comparing PROLASTIN-C and PROLASTIN, adverse events (AEs) were reported at a rate of 0.117 and 0.078 per infusion for PROLASTIN-C and PROLASTIN, respectively, with comparable severity of AEs between treatments. The most common drug related adverse reactions during clinical trials in greater than or equal to 1% of subjects treated with PROLASTIN-C were chills, malaise, headache, rash, hot flush and pruritus. The most serious adverse reaction observed during clinical studies with PROLASTIN-C was an abdominal and extremity rash in one subject. In previous clinical studies with PROLASTIN, reactions were observed in 1.16% of infusions, the most common events being fever (0.77%), light-headedness (0.19%), and dizziness (0.19%).

PROLASTIN and PROLASTIN-C are made from human plasma. Products made from human plasma may contain infectious agents, such as viruses and, theoretically, the Creutzfeldt-Jakob (CJD) agent that can cause disease, and cannot be totally eliminated. There is also the possibility that unknown infectious agents may be present in such products. Individuals with selective IgA deficiencies who have the known antibody against IgA (anti-IgA antibody) should not receive PROLASTIN or PROLASTIN-C, since these patients may experience severe reactions, including anaphylaxis, to IgA which may be present. For additional information on PROLASTIN, please see full prescribing information at www.PROLASTIN.com.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

About Alpha1-Antitrypsin Deficiency

Alpha1-antitrypsin deficiency, also known as AAT deficiency or Alpha-1, is an inherited disorder that causes significant reduction in the naturally occurring protein AAT. It is most common in the Caucasian population of northern Europe and North America. AAT deficiency is also the most common cause of genetic liver disease in children, and genetic emphysema (shortness of breath) in adults. Individuals suffering from AAT deficiency often develop severe obstructive pulmonary disease (COPD) causing disability and premature death. AAT deficiency is estimated to affect 200,000 people in North America and Europe.

About Talecris Biotherapeutics: Inspiration. Dedication. Innovation.

Talecris Biotherapeutics is a global bio-therapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, pulmonology, neurology and hemostasis. For more information, please visit: www.talecris.com.

• Important Disclaimer: Information provided on disabled-world.com is for general informational and educational purposes only, it is not offered as and does not constitute medical advice. In no way are any of the materials presented meant to be a substitute for professional medical care or attention by a qualified practitioner, nor should they be construed as such. Any third party offering or advertising on disabled-world.com does not constitute an endorsement by Disabled World. All trademarks(TM) and registered(R) trademarks are the property of their respective owners. Please report outdated or inaccurate information to us.